14 May 2026
14 May 2026
Four cancer drugs have got the FDA nod in May thus far, with approvals spanning haematological and solid tumour indications.
The approval covers all 27 EU member states, Liechtenstein, Norway, and Iceland.
AstraZeneca’s targeted treatment helps patients live longer, along with preventing cancer recurrence.
While exploratory, the study adds to a growing body of evidence that obesity in T1D may not simply mirror obesity in type 2 diabetes (T2D) or the general population.
This analysis aimed to evaluate muscle strength, changes in body composition assessed by dual-energy DXA, and the correlation between body composition and physical function.
The deal is expected to close in the second quarter of 2026, pending customary closing conditions.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
